RS89504A - 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy - Google Patents

5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy

Info

Publication number
RS89504A
RS89504A YU89504A YUP89504A RS89504A RS 89504 A RS89504 A RS 89504A YU 89504 A YU89504 A YU 89504A YU P89504 A YUP89504 A YU P89504A RS 89504 A RS89504 A RS 89504A
Authority
RS
Serbia
Prior art keywords
progesterone receptor
replacement therapy
hormone replacement
hidroxy
phtalide
Prior art date
Application number
YU89504A
Other languages
English (en)
Inventor
Norbert Schmees
Manfred Lehmann
Ulrike Fuhrmann
Peter Muhn
Christa Hegele-Hartung
Michael Klotzbucher
Original Assignee
Schering Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP02005530A external-priority patent/EP1344776A1/en
Application filed by Schering Ag. filed Critical Schering Ag.
Publication of RS89504A publication Critical patent/RS89504A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/02—1,2-Oxazines; Hydrogenated 1,2-oxazines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Sadašnji pronalazak se odnosi na ne-steroidne progestine opšte formule (I) pri čemu su R1 i R2 nezavisno jedan od drugog -H ili -F, R3 je -CH3 ili -CF3, i Ar je (a) ili (b), ili njihov farmaceutski prihvatljiv derivat ili analog. Ovi progestini su pogodni za selektivno moduliranje sa progesteron receptorom posredovanih dejstva u različitim ciljanim tkivima, posebno u materičnom tkivu spram tikiva dojke. Prema tome, progestini sadašnjeg pronalaska, opciono u kombinaciji sa estrogenima, mogu biti upotrebljeni za kontracepciju (posebno u od estrogena oslobođenim kontraceptivnim sredstvima), terapiji zamene hormona i lečenju ginekoloških poremećaja. Sadašnji pronalazak se dalje odnosi na postupke za selektivno moduliranje sa progesteron receptorom posredovanih dejstava u različitim ciljanim tkivima ili organima.
YU89504A 2002-03-11 2003-03-10 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy RS89504A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36304402P 2002-03-11 2002-03-11
EP02005530A EP1344776A1 (en) 2002-03-11 2002-03-11 5- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -phtalide and 6- 2-hydroxy-3-[1-(3-trifluoromethylphenyl)-cyclopropyl]-propionylamino -4-methyl-2,3-benzoxazin-1-one derivatives with progesterone receptor modulating activity for use in fertility control, hormone replacement therapy and the treatment of gynecological disorders
PCT/EP2003/002441 WO2003075915A1 (en) 2002-03-11 2003-03-10 5-}2-hydroxy-3-`1-(3-trifluoromethylphenyl)-cyclopropyl!-propionylamino}- phtalide and related compounds with progesterone receptor modulating activity for use in fertility control and hormone replacement therapy

Publications (1)

Publication Number Publication Date
RS89504A true RS89504A (en) 2006-10-27

Family

ID=27806515

Family Applications (1)

Application Number Title Priority Date Filing Date
YU89504A RS89504A (en) 2002-03-11 2003-03-10 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy

Country Status (26)

Country Link
US (1) US7388006B2 (sr)
EP (1) EP1482925B1 (sr)
JP (1) JP2005526064A (sr)
CN (1) CN1652768A (sr)
AR (1) AR035904A1 (sr)
AU (1) AU2003209720A1 (sr)
BR (1) BR0308394A (sr)
CA (1) CA2478948A1 (sr)
CR (1) CR7490A (sr)
DE (1) DE60311236T2 (sr)
DK (1) DK1482925T3 (sr)
ES (1) ES2280766T3 (sr)
HR (1) HRP20040923A2 (sr)
IL (1) IL164032A0 (sr)
MX (1) MXPA04008881A (sr)
NO (1) NO20044279L (sr)
NZ (1) NZ535427A (sr)
PE (1) PE20040157A1 (sr)
PL (1) PL372490A1 (sr)
PT (1) PT1482925E (sr)
RS (1) RS89504A (sr)
RU (1) RU2314299C2 (sr)
TW (1) TW200307674A (sr)
UA (1) UA78027C2 (sr)
UY (1) UY27715A1 (sr)
WO (1) WO2003075915A1 (sr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004062182B4 (de) * 2004-12-20 2007-06-06 Bayer Schering Pharma Ag Transdermales Pflaster mit Progesteron A-Spezifische Liganden (PRASL) als Wirkstoff
US20070015689A1 (en) * 2005-06-23 2007-01-18 Alza Corporation Complexation of metal ions with polypeptides
DE102005030294A1 (de) * 2005-06-24 2007-01-04 Schering Ag Nichtsteroidale Progesteronrezeptor-Modulatoren
US7408060B2 (en) 2005-06-24 2008-08-05 Schering Ag Nonsteroidal progesterone receptor modulators
JP4971350B2 (ja) * 2005-12-09 2012-07-11 エフ．ホフマン−ラ ロシュ アーゲー 抗炎症性剤としてのプロピオンアミド化合物
CN101326169B (zh) * 2005-12-09 2011-11-16 霍夫曼-拉罗奇有限公司 作为抗炎剂的糖皮质激素受体调节剂
UY30805A1 (es) * 2006-12-21 2008-07-31 Bayer Schering Pharma Ag Moduladores no esteroides de receptores de progesterona
DE102006061913A1 (de) * 2006-12-21 2008-06-26 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
CN101289408B (zh) * 2007-04-18 2013-02-27 中国科学院上海药物研究所 非甾体类孕激素受体调节剂及其制备方法、药物组合物和用途
DE102007032800A1 (de) * 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
AU2008341138A1 (en) * 2007-12-20 2009-07-02 Teva Women's Health, Inc. Dosage regimens and pharmaceutical compositions and packages for emergency contraception
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
AU2018267059B2 (en) * 2017-05-10 2021-08-12 Ventana Medical Systems, Inc. Stabilized two-part hematoxylin solution utilizing pH adjustment
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
US6245804B1 (en) * 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
DE19723722A1 (de) * 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
NO312255B1 (no) * 2000-06-28 2002-04-15 Pgs Reservoir Consultants As Verktöy for gjennomhulling av et langsgående veggparti av et fôringsrör
DE10038639A1 (de) * 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
WO2002054064A2 (en) * 2000-12-28 2002-07-11 Schering Ag Method for screening for progesterone receptor isoform-specific ligands

Also Published As

Publication number Publication date
UY27715A1 (es) 2003-08-29
IL164032A0 (en) 2005-12-18
RU2314299C2 (ru) 2008-01-10
EP1482925B1 (en) 2007-01-17
ES2280766T3 (es) 2007-09-16
BR0308394A (pt) 2005-01-25
AU2003209720A1 (en) 2003-09-22
DK1482925T3 (da) 2007-05-14
CN1652768A (zh) 2005-08-10
AR035904A1 (es) 2004-07-28
JP2005526064A (ja) 2005-09-02
RU2004130430A (ru) 2005-08-10
US20030232824A1 (en) 2003-12-18
CA2478948A1 (en) 2003-09-18
NO20044279L (no) 2004-12-08
US7388006B2 (en) 2008-06-17
PT1482925E (pt) 2007-04-30
DE60311236D1 (de) 2007-03-08
NZ535427A (en) 2006-08-31
UA78027C2 (en) 2007-02-15
EP1482925A1 (en) 2004-12-08
CR7490A (es) 2006-02-07
WO2003075915A1 (en) 2003-09-18
TW200307674A (en) 2003-12-16
DE60311236T2 (de) 2008-02-14
HRP20040923A2 (en) 2004-12-31
PL372490A1 (en) 2005-07-25
PE20040157A1 (es) 2004-06-03
MXPA04008881A (es) 2004-12-07

Similar Documents

Publication Publication Date Title
RS89504A (en) 5-(2-hidroxy-3-/1-(3-trifluoromethylphenyl)-cyclopropyl/-propionylamino)-phtalide and related compounds with progesterone receptor modulating activity for use ine fertility control and hormone replacement therapy
JP2005526064A5 (sr)
US4372951A (en) Vaginal delivery for physiologic follicular-luteal steroid treatment
DK1272504T3 (da) 8.Beta-hydrocarbylsubstituerede östradiener til anvendelse som selektive östrogener
TW200716137A (en) Tanaproget compositions containing ethinyl estradiol
AR035564A1 (es) Moduladores selectivos de receptores de estrogenos en combinacion con estrogenos
AU2012282061B2 (en) Treatment of excessive menstrual bleeding associated with uterine fibroids
Troulis et al. Endoscopic vertical ramus osteotomy: early clinical results
IL266823A (en) Use of chymase inhibitors to treat endometriosis, post-operative fibrosis and diseases associated with fibrosis formation
BR0008437A (pt) Inibidores esteróides de sulfatase e métodos parafabricação e uso dos mesmos
ES2320662T3 (es) Hormonoterapia restitutiva y tratamiento para la depresion con dienogest.
WO2008122439A2 (en) Dr0spiren0ne/17beta-estradi0l regimen, pharmaceutical combination product and kit for performing this regimen
ES2295050T3 (es) Mesoprogestinas para el tratamiento y la prevencion de trastornos ginecologicos benignos dependientes de hormonas.
EDGERTON JR et al. Fixation and plastic repair after partial mandibular resection
RU2006145077A (ru) Применение комбинации из этинилэстрадиола и ацетата хлормадинона для приготовления лекарственного средства
WO2020261602A1 (ja) 医薬組成物
Hopkins et al. Large tongue flaps to close massive palatal defects
Lyman et al. Second-Degree Perineal Laceration
Scheck et al. LLETZ during lactation causing cervical stenosis and haematometra
TH63281A (th) โพรเจสทินที่ไม่เป็นสเตอรอยด์
Johnson Nerve Block in Painless Childbirth
RU2201233C1 (ru) Способ профилактики хронических циститов в период менопаузы
Masoumi et al. Comparison between uterine bleeding and spotting pattern in menopausal women using tibolone, HRT and calcium supplement
Tiwari et al. Uterine cystic glandular hyperplasia with pyometra in an Alsatian bitch and its treatment.
KR20080072087A (ko) Ｅｒ-베타 선택적 물질의 전구약물, 그의 제조 방법 및그것을 포함하는 제약 조성물